Longeveron (LGVN) Competitors $1.70 -0.02 (-1.16%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (-0.29%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LGVN vs. CHRS, MIST, FATE, PROC, NKTX, XBIT, SLN, IMUX, GALT, and ANIXShould you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Coherus BioSciences (CHRS), Milestone Pharmaceuticals (MIST), Fate Therapeutics (FATE), Procaps Group (PROC), Nkarta (NKTX), XBiotech (XBIT), Silence Therapeutics (SLN), Immunic (IMUX), Galectin Therapeutics (GALT), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Longeveron vs. Coherus BioSciences Milestone Pharmaceuticals Fate Therapeutics Procaps Group Nkarta XBiotech Silence Therapeutics Immunic Galectin Therapeutics Anixa Biosciences Longeveron (NASDAQ:LGVN) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment, community ranking and earnings. Which has higher earnings and valuation, LGVN or CHRS? Longeveron has higher earnings, but lower revenue than Coherus BioSciences. Longeveron is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLongeveron$2.39M10.61-$21.41M-$6.28-0.27Coherus BioSciences$266.96M0.37-$237.89M$0.194.48 Do institutionals & insiders have more ownership in LGVN or CHRS? 10.0% of Longeveron shares are owned by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are owned by institutional investors. 19.1% of Longeveron shares are owned by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer LGVN or CHRS? In the previous week, Coherus BioSciences had 1 more articles in the media than Longeveron. MarketBeat recorded 5 mentions for Coherus BioSciences and 4 mentions for Longeveron. Coherus BioSciences' average media sentiment score of 0.47 beat Longeveron's score of 0.45 indicating that Coherus BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coherus BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer LGVN or CHRS? Coherus BioSciences received 431 more outperform votes than Longeveron when rated by MarketBeat users. However, 94.74% of users gave Longeveron an outperform vote while only 65.36% of users gave Coherus BioSciences an outperform vote. CompanyUnderperformOutperformLongeveronOutperform Votes1894.74% Underperform Votes15.26%Coherus BioSciencesOutperform Votes44965.36% Underperform Votes23834.64% Is LGVN or CHRS more profitable? Coherus BioSciences has a net margin of -0.15% compared to Longeveron's net margin of -967.49%. Coherus BioSciences' return on equity of 0.00% beat Longeveron's return on equity.Company Net Margins Return on Equity Return on Assets Longeveron-967.49% -142.43% -100.84% Coherus BioSciences -0.15%N/A -24.44% Do analysts prefer LGVN or CHRS? Longeveron presently has a consensus price target of $8.67, suggesting a potential upside of 409.80%. Coherus BioSciences has a consensus price target of $5.38, suggesting a potential upside of 531.61%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Longeveron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Longeveron 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more volatility & risk, LGVN or CHRS? Longeveron has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. SummaryCoherus BioSciences beats Longeveron on 11 of the 18 factors compared between the two stocks. Remove Ads Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGVN vs. The Competition Export to ExcelMetricLongeveronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.38M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.277.2024.5919.03Price / Sales10.61225.82383.9393.17Price / CashN/A65.6738.1634.64Price / Book0.636.476.944.33Net Income-$21.41M$141.90M$3.20B$247.06M7 Day Performance-3.41%-3.02%-2.30%-0.53%1 Month Performance11.11%-4.63%3.07%-3.74%1 Year Performance-45.69%-8.61%11.15%1.72% Longeveron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGVNLongeveron2.5411 of 5 stars$1.70-1.2%$8.67+409.8%-50.1%$25.38M$2.39M-0.2720Short Interest ↑Gap UpCHRSCoherus BioSciences3.6281 of 5 stars$0.95-7.6%$5.38+464.5%-60.7%$110.35M$266.96M-11.90330MISTMilestone Pharmaceuticals2.1472 of 5 stars$2.05+7.9%$17.00+729.3%+11.0%$109.38M$1M-2.5330Gap UpHigh Trading VolumeFATEFate Therapeutics3.9522 of 5 stars$0.94+2.9%$5.50+484.6%-87.5%$107.81M$13.63M-0.57550Positive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-68.3%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeNKTXNkarta2.8983 of 5 stars$1.55+3.3%$15.00+867.7%-86.1%$105.85MN/A-0.82140Earnings ReportAnalyst ForecastNews CoverageGap UpXBITXBiotech1.2769 of 5 stars$3.46+0.6%N/A-60.0%$105.49M$4.01M-3.20100Short Interest ↓Positive NewsGap UpSLNSilence Therapeutics2.2136 of 5 stars$3.49-2.0%$40.67+1,065.2%-84.6%$104.46M$43.26M-2.22100Positive NewsIMUXImmunic2.6268 of 5 stars$1.17+1.7%$12.67+982.6%-6.3%$103.59MN/A-0.9570Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageGALTGalectin Therapeutics1.5596 of 5 stars$1.65+3.8%$11.00+566.7%-30.8%$103.56MN/A-2.269Gap UpANIXAnixa Biosciences3.1789 of 5 stars$3.20+1.3%$9.00+181.3%+0.6%$103.03M$210,000.00-8.215Analyst ForecastAnalyst RevisionNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies CHRS Alternatives MIST Alternatives FATE Alternatives PROC Alternatives NKTX Alternatives XBIT Alternatives SLN Alternatives IMUX Alternatives GALT Alternatives ANIX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGVN) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGVN Stock Free LGVN Stock Alerts